The FDA approved a supplement to new drug application NDA207924 for baricitinib on 25 September 2026, filed by Eli Lilly and Company. The record does not state whether the change is an indication, a formulation, a label revision or a manufacturing matter.
The reason it belongs in an oncology briefing is the malignancy warning. Janus kinase inhibitors carry a boxed warning that includes malignancy, derived from ORAL Surveillance, in which tofacitinib was compared against tumour necrosis factor inhibitors in rheumatoid arthritis patients with cardiovascular risk factors. Lymphoma and lung cancer were among the malignancies reported more often.
Oncologists meet this in two places. A patient with a history of malignancy being considered for a JAK inhibitor by a rheumatologist or dermatologist, where the question is whether the cancer history alters the decision - and the label's answer is cautious rather than prohibitive. And a new cancer arising in a patient already on one, where the drug belongs in the history. Any change to a label carrying that warning is worth reading rather than filing, and the revised label is the document to check, not this record.
- Record current or previous Janus kinase inhibitor exposure when taking an oncology history.
- The class boxed warning includes malignancy, from a trial in rheumatoid arthritis with cardiovascular risk factors.
- The record does not say what this supplement changed; the revised label is the source to check.
- A cancer history does not prohibit a JAK inhibitor, but it changes the discussion.
- A US supplement implies no CDSCO change; Indian labelling is unaffected.
Why it matters
A drug class with a boxed malignancy warning is one oncologists are consulted about, and label changes to it should not pass unread.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for oncology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free